SCHEMBL15906155

SCHEMBL15906155

COc1ccc(Cn2ccccc2=O)cc1-c1cccc(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
PDE4B Q07343 2/20 0.46
TP53 P04637 3/20 0.42
LMNA P02545 2/20 0.42
HTR7 P34969 4/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CHEK1 O14757 1/20 0.40
NEK2 P51955 1/20 0.40
LIMK1 P53667 1/20 0.40
TYRO3 Q06418 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
KLKB1 P03952 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TLR9 Q9NR96 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15906118 0.89 ALDH1A1 (0.41) MAPTPDE4BHTR7POLBMEN1
SCHEMBL4326721 0.87 PDE4B (0.61) MAPTPDE4BTP53HTR7POLB
SCHEMBL15906166 0.85 MAPT (0.44) MAPTPDE4BTP53LMNAPOLB
SCHEMBL7913026 0.84 PDE4B (0.43) PDE4BHTR7KLKB1HDAC8
SCHEMBL15906141 0.84 MAPT (0.46) MAPTPDE4BTP53LMNAPOLB
SCHEMBL3807659 0.84 PDE4B (0.43) PDE4BHTR7KLKB1
SCHEMBL3805746 0.84 MAPK1 (0.45) MAPTPDE4BPOLBMEN1KMT2A
SCHEMBL15906132 0.83 PDE4B (0.43) MAPTPDE4BTP53LMNAHTR7
SCHEMBL15906143 0.83 CYP11B1 (0.43) MAPTPDE4BTP53LMNAMEN1
SCHEMBL13578412 0.83 PDE4B (0.41) PDE4BHTR7KLKB1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140301999-A1 BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS DECODE GENETICS EHF (IS) 2014-10-09 US disclosed
US-8791267-B2 Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders DECODE GENETICS EHF (IS) 2014-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140301999-A1 BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS PDE4A, PDE4B, PDE3B MAPT 1932/4885PDE4B 2/4885TP53 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.